X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs BIOCON LTD - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES BIOCON LTD PIRAMAL ENTERPRISES/
BIOCON LTD
 
P/E (TTM) x 36.6 82.9 44.1% View Chart
P/BV x 3.0 7.8 39.0% View Chart
Dividend Yield % 0.8 0.2 503.7%  

Financials

 PIRAMAL ENTERPRISES   BIOCON LTD
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
BIOCON LTD
Mar-17
PIRAMAL ENTERPRISES/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs2,0951,162 180.3%   
Low Rs1,025483 212.4%   
Sales per share (Unadj.) Rs492.8194.6 253.3%  
Earnings per share (Unadj.) Rs72.634.4 210.9%  
Cash flow per share (Unadj.) Rs94.748.3 196.2%  
Dividends per share (Unadj.) Rs21.001.00 2,100.0%  
Dividend yield (eoy) %1.30.1 1,106.8%  
Book value per share (Unadj.) Rs862.5241.9 356.6%  
Shares outstanding (eoy) m172.56200.00 86.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.24.2 74.9%   
Avg P/E ratio x21.523.9 90.0%  
P/CF ratio (eoy) x16.517.0 96.7%  
Price / Book Value ratio x1.83.4 53.2%  
Dividend payout %28.92.9 995.8%   
Avg Mkt Cap Rs m269,194164,440 163.7%   
No. of employees `0004.09.2 43.5%   
Total wages/salary Rs m17,9397,470 240.1%   
Avg. sales/employee Rs Th21,190.34,213.9 502.9%   
Avg. wages/employee Rs Th4,470.1809.0 552.6%   
Avg. net profit/employee Rs Th3,120.0745.2 418.7%   
INCOME DATA
Net Sales Rs m85,03738,911 218.5%  
Other income Rs m2,3381,571 148.8%   
Total revenues Rs m87,37440,482 215.8%   
Gross profit Rs m34,9919,795 357.2%  
Depreciation Rs m3,8172,772 137.7%   
Interest Rs m20,310260 7,811.5%   
Profit before tax Rs m13,2028,334 158.4%   
Minority Interest Rs m1,699163 1,042.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,2811,616 141.2%   
Profit after tax Rs m12,5206,881 182.0%  
Gross profit margin %41.125.2 163.5%  
Effective tax rate %17.319.4 89.1%   
Net profit margin %14.717.7 83.3%  
BALANCE SHEET DATA
Current assets Rs m87,59040,477 216.4%   
Current liabilities Rs m185,57816,783 1,105.8%   
Net working cap to sales %-115.260.9 -189.2%  
Current ratio x0.52.4 19.6%  
Inventory Days Days3160 52.1%  
Debtors Days Days4883 57.4%  
Net fixed assets Rs m108,52345,073 240.8%   
Share capital Rs m3451,000 34.5%   
"Free" reserves Rs m148,48147,377 313.4%   
Net worth Rs m148,82648,377 307.6%   
Long term debt Rs m144,95721,082 687.6%   
Total assets Rs m482,39493,942 513.5%  
Interest coverage x1.733.1 5.0%   
Debt to equity ratio x1.00.4 223.5%  
Sales to assets ratio x0.20.4 42.6%   
Return on assets %6.87.6 89.5%  
Return on equity %8.414.2 59.1%  
Return on capital %12.012.6 94.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,00112,988 115.5%   
Fx outflow Rs m5,1507,899 65.2%   
Net fx Rs m9,8515,089 193.6%   
CASH FLOW
From Operations Rs m-100,3936,400 -1,568.6%  
From Investments Rs m-24,202-4,985 485.5%  
From Financial Activity Rs m135,705-1,775 -7,645.3%  
Net Cashflow Rs m11,110-473 -2,348.8%  

Share Holding

Indian Promoters % 52.9 40.4 130.9%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 4.0 8.4 47.6%  
FIIs % 26.6 10.7 248.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 19.9 82.9%  
Shareholders   93,274 109,995 84.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Feb 23, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS